ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 507,30
0,83%
Dow Jones
42 706,56
0,00%
DAX
20 357,77
0,73%
Brent Oil
76,755
0,84%
Bitcoin
100 639,00
-1,61%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Celldex Therapeutics Inc (CLDX) Cours

Celldex Therapeutics Inc

Celldex Therapeutics Inc (CLDX)

NASDAQ
26,58
-0,23
(-0,86%)
Fermé 07 Janvier 10:00PM
Retardé de 15 minutes
27,20
0,62
( 2,33% )
Avant marché: 2:39PM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
27,20
Prix Achat
25,88
Prix Vente
27,30
Volume échangé
205
0,00 Fourchette du Jour 0,00
22,9291 Plage de 52 semaines 53,18
Cap du marché
1,805B
Clôture Veille
26,58
Ouverture
-
Dernière Transaction
1
@
27.19
Dernière heure de transaction
14:35:54
Volume financier
-
VWAP
-
Volume moyen (3 m)
1 000 700
Actions en circulation
66 344 236
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-12,47
Bénéfice par action (BPA)
-2,13
Chiffre d'affairess
6,88M
Bénéfice net
-141,43M

À propos de Celldex Therapeutics Inc

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more

Secteur
In Vitro,in Vivo Diagnostics
Industrie
In Vitro,in Vivo Diagnostics
Site Web
www.celldex.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Celldex Therapeutics Inc est coté dans le secteur In Vitro,in Vivo Diagnostics de la NASDAQ avec le ticker CLDX. Le dernier cours de clôture d'Celldex Therapeutics était de US$26,58. Au cours de la dernière année, les actions de Celldex Therapeutics ont été négociées dans une fourchette de prix de US$ 22,9291 à US$ 53,18.

Celldex Therapeutics compte actuellement 66 344 236 actions en circulation. La capitalisation boursière d'Celldex Therapeutics est de US$1,76 milliard. Celldex Therapeutics a un ratio cours/bénéfice (ratio PE) de -12.47.

Flux d'options Celldex Therapeutics (CLDX)

Voir le flux d'options complet

Flux global

Baissier

Prime nette

-213k

Calls / Puts

0,00%

Ach. / Vent.

100,00%

OTM / ITM

0,00%

Sweeps Ratio

0,00%

CLDX Dernières nouvelles

Plus de nouvelles

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis...

19 Décembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

20 Novembre 2024
Edgar (US Regulatory)

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

20 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Novembre 2024
Edgar (US Regulatory)

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:...

11 Novembre 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

08 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
11.847.2555205047325.3627.224.55102493526.34791171CS
40.642.4096385542226.5627.2323.9491668925.79445039CS
12-3.09-10.201386596230.2930.4822.9291100070026.47862981CS
26-8.73-24.297244642435.934722.929196936132.05979897CS
52-11.8-30.25641025643953.1822.929189333035.98178037CS
156-8.73-24.297244642435.9353.1819.8569255633.86293703CS
26024.59942.145593872.6157.21.576060327.03629611CS

CLDX - Frequently Asked Questions (FAQ)

What is the current Celldex Therapeutics share price?
The current share price of Celldex Therapeutics is US$ 27,20
How many Celldex Therapeutics shares are in issue?
Celldex Therapeutics has 66 344 236 shares in issue
What is the market cap of Celldex Therapeutics?
The market capitalisation of Celldex Therapeutics is USD 1,76B
What is the 1 year trading range for Celldex Therapeutics share price?
Celldex Therapeutics has traded in the range of US$ 22,9291 to US$ 53,18 during the past year
What is the PE ratio of Celldex Therapeutics?
The price to earnings ratio of Celldex Therapeutics is -12,47
What is the cash to sales ratio of Celldex Therapeutics?
The cash to sales ratio of Celldex Therapeutics is 256,32
What is the reporting currency for Celldex Therapeutics?
Celldex Therapeutics reports financial results in USD
What is the latest annual turnover for Celldex Therapeutics?
The latest annual turnover of Celldex Therapeutics is USD 6,88M
What is the latest annual profit for Celldex Therapeutics?
The latest annual profit of Celldex Therapeutics is USD -141,43M
What is the registered address of Celldex Therapeutics?
The registered address for Celldex Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Celldex Therapeutics website address?
The website address for Celldex Therapeutics is www.celldex.com
Which industry sector does Celldex Therapeutics operate in?
Celldex Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
XTIAXTI Aerospace Inc
US$ 0,21345
(142,56%)
649,95M
HOTHHoth Therapeutics Inc
US$ 1,60
(95,22%)
33,07M
IMRXImmuneering Corporation
US$ 4,4412
(88,19%)
44,95M
CDTConduit Pharmaceuticals Inc
US$ 0,13
(79,81%)
85,25M
RIMEAlgorhythm Holdings Inc
US$ 0,2474
(70,86%)
187,98M
LFWDLifeward Ltd
US$ 1,8997
(-37,51%)
718,37k
SLRNACELYRIN Inc
US$ 2,19
(-37,25%)
872,24k
AMSTAmesite Inc
US$ 2,83
(-30,12%)
80,74k
BOXLBoxlight Corporation
US$ 1,18
(-29,76%)
1,89M
SRZNSurrozen Inc
US$ 11,01
(-22,63%)
7
XTIAXTI Aerospace Inc
US$ 0,21345
(142,56%)
649,95M
RIMEAlgorhythm Holdings Inc
US$ 0,2474
(70,86%)
187,98M
SVMHSRIVARU Holding Ltd
US$ 0,0672
(45,14%)
131,32M
CDTConduit Pharmaceuticals Inc
US$ 0,13
(79,81%)
85,25M
CEROCERo Therapeutics Holdings Inc
US$ 0,0577
(36,41%)
72,98M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CLDX
Celldex Therapeutics
BIT
P1HOH2
BNP Paribas Issuance
BIT
UI453X
UniCredit
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés